drugset / Trial / NCT05187338
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).
Timeline
- Start
- 2021-11-01
- Primary completion
- 2029-10-30
- Completion
- 2035-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |